Transcend: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

IRB Number: STU00201825
ClinicalTrials.gov Identifier: NCT02631044
PI Name: Leo Gordon
Eligibility Criteria:

  • Participants must have any of the following types of lymphoma: Diffuse Large B-cell Lymphoma – DLBCL; Transformed DLBCL from indolent histology; Follicular Lymphoma Grade 3B; Mantle Cell Lymphoma.
  • Participants must have cancer that has returned or has not responded to other treatment.
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Leo I. Gordon, MD

Leo I. Gordon, MD

Primary Specialty: Hematology and Medical Oncology


Platform: An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies

IRB Number: STU00206138
ClinicalTrials.gov Identifier: NCT03310619
PI Name: Reem Karmali
Eligibility Criteria:

  • Participants must have a confirmed diagnosis of Relapsed/Refractory B-Cell Malignancies

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Reem Karmali, MD

Reem Karmali, MD

Primary Specialty: Hematology and Medical Oncology


Transcend CLL: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IRB Number: STU00208648
ClinicalTrials.gov Identifier: NCT03331198
PI Name: Shuo Ma
Eligibility Criteria:

  • Participants must have any of the following types of lymphoma: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
  • You must have received 2 or 3 prior treatments for your CLL or SLL
  • Participants must have cancer that has returned or has not responded to other treatment.
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Shuo Ma, MD  PhD

Shuo Ma, MD PhD

Primary Specialty: Hematology and Medical Oncology


Pilot: A Phase 2 study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

IRB Number: STU00210077
ClinicalTrials.gov Identifier: NCT03483103
PI Name: Leo Gordon
Eligibility Criteria:

  • Participants must have a confirmed diagnosis of aggressive B-cell Non-Hodgkin Lymphoma (NHL) and have received a single previous line of therapy.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Leo I. Gordon, MD

Leo I. Gordon, MD

Primary Specialty: Hematology and Medical Oncology


KarMMa-3: A Phase 3, Multicenter, Randomized, Open- Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

IRB Number: STU00208507
ClinicalTrials.gov Identifier: NCT03651128
PI Name: Leo Gordon
Eligibility Criteria:

  • Documented diagnosis of Multiple Myeloma and measurable disease
  • Able to understand the nature of this trial and provide written informed consent; 3)
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Leo I. Gordon, MD

Leo I. Gordon, MD

Primary Specialty: Hematology and Medical Oncology


Transform: A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas

IRB Number: STU00209903
ClinicalTrials.gov Identifier: NCT03575351
PI Name: Reem Karmali
Eligibility Criteria:

  • B-Cell non-Hodgkin lymphoma, specifically:
    • Diffuse large B-cell lymphoma (DLBCL)
    • Follicular lymphoma Grade 3B
    • Primary mediastinal (thymic) large B-cell lymphoma
    • T cell/histiocyte-rich B cell lymphoma

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Reem Karmali, MD

Reem Karmali, MD

Primary Specialty: Hematology and Medical Oncology


Cartitude-2: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)

IRB Number: STU00210994
ClinicalTrials.gov Identifier: NCT04133636
PI Name: Seema Singhal
Eligibility Criteria:

  • Participants must have a diagnosis of multiple myeloma
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Seema Singhal, MD

Seema Singhal, MD

Primary Specialty: Hematology